MA51613A - Polythérapie pour le traitement ou la prévention du cancer - Google Patents

Polythérapie pour le traitement ou la prévention du cancer

Info

Publication number
MA51613A
MA51613A MA051613A MA51613A MA51613A MA 51613 A MA51613 A MA 51613A MA 051613 A MA051613 A MA 051613A MA 51613 A MA51613 A MA 51613A MA 51613 A MA51613 A MA 51613A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer
prevention
treatment
Prior art date
Application number
MA051613A
Other languages
English (en)
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808628.0A external-priority patent/GB201808628D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of MA51613A publication Critical patent/MA51613A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA051613A 2018-01-19 2019-01-18 Polythérapie pour le traitement ou la prévention du cancer MA51613A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808628.0A GB201808628D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
MA51613A true MA51613A (fr) 2020-11-25

Family

ID=65228590

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051613A MA51613A (fr) 2018-01-19 2019-01-18 Polythérapie pour le traitement ou la prévention du cancer

Country Status (18)

Country Link
US (3) US20210060095A1 (fr)
EP (1) EP3740218A1 (fr)
JP (1) JP2021516216A (fr)
KR (1) KR20200111183A (fr)
CN (1) CN111629739A (fr)
AU (1) AU2019210002A1 (fr)
BR (1) BR112020014676A2 (fr)
CA (1) CA3088413A1 (fr)
CL (1) CL2020001888A1 (fr)
CO (1) CO2020010013A2 (fr)
IL (1) IL275949A (fr)
MA (1) MA51613A (fr)
MX (1) MX2020007671A (fr)
NI (1) NI202000052A (fr)
PH (1) PH12020551080A1 (fr)
SG (1) SG11202006871YA (fr)
TW (1) TW201938180A (fr)
WO (1) WO2019141996A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202310861A (zh) * 2021-09-14 2023-03-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
WO2023041574A1 (fr) * 2021-09-14 2023-03-23 4D Pharma Research Limited Compositions comprenant des souches bactériennes
CN115569193B (zh) * 2021-10-09 2024-04-02 施慧达药业集团(吉林)有限公司 戈氏梭菌芽孢联合帕博利珠单抗的应用及治疗结肠癌药物和戈氏梭菌芽孢冻干粉制备方法
WO2023072968A1 (fr) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprenant des souches bactériennes
KR102850602B1 (ko) * 2023-01-19 2025-08-26 재단법인 대구경북첨단의료산업진흥재단 골 질환 예방 또는 치료를 위한 신규 유산균 및 이의 배양액

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20100168410A1 (en) 2006-10-27 2010-07-01 Pfizer Products Inc. Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR102661603B1 (ko) * 2015-06-01 2024-04-29 더 유니버서티 오브 시카고 공생 미생물총의 조작에 의한 암의 치료
WO2017085520A1 (fr) * 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprenant des souches bactériennes
WO2018215782A1 (fr) * 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprenant des souches bactériennes

Also Published As

Publication number Publication date
IL275949A (en) 2020-08-31
CL2020001888A1 (es) 2020-12-18
BR112020014676A2 (pt) 2020-12-08
CN111629739A (zh) 2020-09-04
US20230048366A1 (en) 2023-02-16
JP2021516216A (ja) 2021-07-01
CO2020010013A2 (es) 2020-08-31
NI202000052A (es) 2021-01-20
US20240016861A1 (en) 2024-01-18
MX2020007671A (es) 2020-09-14
PH12020551080A1 (en) 2021-08-02
SG11202006871YA (en) 2020-08-28
AU2019210002A1 (en) 2020-08-13
TW201938180A (zh) 2019-10-01
CA3088413A1 (fr) 2019-07-25
WO2019141996A1 (fr) 2019-07-25
KR20200111183A (ko) 2020-09-28
US20210060095A1 (en) 2021-03-04
EP3740218A1 (fr) 2020-11-25

Similar Documents

Publication Publication Date Title
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3600281A4 (fr) Traitement d'association pour le traitement ou la prévention de tumeurs
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3570844A4 (fr) Azolopyrimidine pour le traitement de troubles liés au cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3533466A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3766497A4 (fr) Médicament pour le traitement de la toux
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3411073A4 (fr) Combinaisons pour le traitement du cancer